ISO 15189:2022 - Medical Laboratory Examination Processes Professional Free Practice Test — 30 Questions

Question 1

A medical laboratory receives a blood sample for a critical diagnostic test. Upon initial inspection, the phlebotomist notes that the patient\'s full name is missing from the primary tube label, only a partial identifier is present. Furthermore, the collection timestamp on the sample indicates it was drawn 72 hours prior to arrival at the laboratory, exceeding the recommended stability period for the specific analyte requested. The laboratory\'s standard operating procedure for sample acceptance, aligned with ISO 15189:2022, mandates that all samples must have complete patient identification and be within the acceptable pre-examination phase stability limits. What is the most appropriate course of action for the laboratory personnel in this situation?

Accepted Answer

Reject the sample, document the reasons for rejection, and immediately inform the requesting healthcare provider.

Question 2

A medical laboratory accredited to ISO 15189:2022 frequently refers certain specialized biochemical assays to a highly reputable external reference laboratory due to the complexity and infrequent demand for these tests. The laboratory director is reviewing the laboratory\'s quality management system concerning these referred examinations. Which of the following actions is most critical for the laboratory to demonstrate compliance with the standard\'s requirements for ensuring the quality of all examinations, whether performed in-house or externally?

Accepted Answer

Establishing a formal, documented agreement with the external reference laboratory that specifies quality requirements, reporting formats, and the laboratory's right to audit the external provider's processes.

Question 3

A clinical laboratory accredited to ISO 15189:2022 receives a blood sample for a complex biochemical assay. Upon visual inspection, the phlebotomist notes that the serum appears significantly hemolyzed, a condition not explicitly listed as an absolute rejection criterion in the laboratory\'s standard operating procedure but known to potentially interfere with the assay\'s accuracy. The requesting physician, Dr. Aris Thorne, is currently unavailable. What is the most appropriate course of action for the laboratory to ensure compliance with quality management principles and patient safety?

Accepted Answer

Document the observed hemolysis, inform Dr. Thorne's designated contact person or department about the sample condition and the potential impact on results, and await further instructions before proceeding with the examination.

Question 4

A senior laboratory technologist at a busy diagnostic facility notices that a batch of a critical reagent for a complex serological assay, intended for use in detecting specific autoantibodies, was procured from a new, unvetted external vendor by a junior colleague. This vendor was not on the laboratory\'s approved supplier list, and the reagent was not subjected to the standard incoming quality control checks as per the laboratory\'s documented procedures. What is the most appropriate immediate action and subsequent systemic response required by the laboratory in accordance with ISO 15189:2022 principles?

Accepted Answer

Immediately quarantine and cease the use of the unapproved reagent, conduct a thorough investigation into its procurement and potential impact on previously reported patient results, and initiate corrective actions to reinforce supplier qualification and material acceptance protocols.

Question 5

A clinical laboratory receives a serum sample for a routine electrolyte panel. Upon visual inspection, the technologist notes significant hemolysis, indicated by a visibly pinkish-red discoloration of the serum. The laboratory\'s standard operating procedure for potassium analysis specifies that hemolysis can interfere with the assay, potentially leading to falsely elevated results. Considering the requirements of ISO 15189:2022 regarding pre-examination processes and the laboratory\'s responsibility for ensuring the suitability of samples, what is the most appropriate course of action for the laboratory?

Accepted Answer

Reject the sample due to visible hemolysis and inform the requesting clinician of the reason for rejection, requesting a new sample.

Question 6

A medical laboratory accredited to ISO 15189:2022 is performing a complex immunoassay for a critical analyte. The laboratory utilizes a commercially available calibrator lot, which is stated by the manufacturer to be traceable to a primary reference measurement procedure. To fulfill the requirements of the standard regarding the traceability of measurements, what is the most critical action the laboratory must undertake concerning this calibrator?

Accepted Answer

Obtain and maintain documentation from the calibrator manufacturer that substantiates the traceability of the calibrator's assigned values to recognized national or international standards or reference measurement procedures.

Question 7

A medical laboratory receives a serum sample for a requested biochemical panel. Upon initial inspection, the specimen container is correctly labeled with the patient\'s hospital identification number and the date of collection. However, the accompanying request form, which is electronically generated, fails to populate the patient\'s full name and date of birth, displaying only the hospital ID number. The laboratory\'s standard operating procedure for sample reception, developed in accordance with ISO 15189:2022 requirements for sample acceptance, mandates that all identifying information on the sample container must be verifiable against the request form. What is the most appropriate action for the laboratory to take in this situation?

Accepted Answer

Reject the sample and notify the requesting clinician of the missing critical patient identification details.

Question 8

A critical diagnostic assay for a rare autoimmune disorder is requested by a remote clinic. The sample, collected at the clinic, is transported via a standard courier service under ambient temperature conditions, despite the assay\'s known sensitivity to temperature fluctuations and the extended transit time. Upon arrival at the laboratory, the sample appears visually normal, and the analytical testing proceeds without any instrument flags or deviations from standard operating procedures. However, the patient\'s clinical presentation is incongruent with the reported laboratory result. Which of the following best describes the laboratory\'s primary responsibility in this situation, according to ISO 15189:2022 principles?

Accepted Answer

Ensuring the integrity and suitability of the sample throughout the entire examination process, including pre-examination phases like transport.

Question 9

A medical laboratory receives a blood sample for a complex diagnostic panel requiring multiple specific assays. Upon initial inspection, it is determined that the collected volume of plasma is significantly less than the minimum required for all requested tests to be performed according to the validated analytical procedures. The sample was collected by an external healthcare provider. What is the most appropriate action for the laboratory to take in accordance with ISO 15189:2022 principles regarding sample integrity and acceptance?

Accepted Answer

Reject the sample and inform the requester of the insufficient volume, documenting the reason for rejection.

Question 10

A medical laboratory receives a blood sample for a complex biochemical assay. Upon visual inspection, the phlebotomist notes that the sample appears hemolyzed, a condition that is known to interfere with the accuracy of the specific assay requested. The laboratory\'s standard operating procedure for sample handling includes a step for visual inspection and rejection of visibly compromised samples. However, the requesting physician\'s office is experiencing exceptionally high patient volumes, and the physician has verbally requested that the lab proceed with the testing, stating that any result is better than no result. Which of the following actions best aligns with the principles of ISO 15189:2022 regarding sample acceptance and the provision of reliable examination results?

Accepted Answer

Reject the sample due to visible hemolysis, document the reason for rejection, and inform the requesting healthcare professional of the issue and the need for a new sample.

Question 11

A clinical pathology laboratory, accredited under ISO 15189:2022, is considering the implementation of a novel automated immunoassay analyzer for the detection of specific cardiac biomarkers. The manufacturer provides extensive validation data demonstrating excellent performance. However, the laboratory\'s quality manager is concerned about potential variations in performance due to local environmental factors, reagent lot differences, and the specific patient demographics served. What is the most critical step the laboratory must undertake to ensure the integrity of patient results generated by this new system, in accordance with the standard\'s requirements for the examination process?

Accepted Answer

Conduct a thorough verification of the analytical system's performance characteristics using the laboratory's own reagents, personnel, and anticipated patient sample matrix.

Question 12

A clinical laboratory receives a blood sample for a coagulation test. Upon visual inspection, it is noted that the sample was collected in a tube with the incorrect anticoagulant, potentially affecting the accuracy of the intended assay. According to the principles outlined in ISO 15189:2022 for ensuring the quality of examination procedures, what is the most appropriate immediate action for the laboratory to take?

Accepted Answer

Inform the requesting healthcare professional about the discrepancy and discuss the implications for proceeding with the examination.

Question 13

A medical laboratory accredited to ISO 15189:2022 discovers that a patient\'s blood sample, collected for a routine coagulation profile, was processed using a vacuum tube that had passed its expiry date. The expired tube contained a citrate anticoagulant. The laboratory\'s standard operating procedure (SOP) for sample collection clearly states the requirement to use only in-date collection devices. What is the most appropriate immediate action the laboratory\'s quality manager should initiate to address this situation in accordance with the principles of ISO 15189:2022?

Accepted Answer

Document the incident as a non-conformity and initiate a root cause analysis to identify systemic issues in reagent and consumable management.

Question 14

A medical laboratory accredited to ISO 15189:2022 is reviewing its quality management system. A recent internal audit identified a trend of slightly elevated results for a specific analyte when samples were collected from a remote patient service center, compared to samples collected at the main laboratory. The analytical phase for this analyte is known to be robust and exhibits excellent intra-laboratory precision. Which of the following actions most directly addresses the laboratory\'s obligation under ISO 15189:2022 to ensure the suitability of the entire examination process, particularly concerning the observed discrepancy?

Accepted Answer

Intensify the validation of the analytical method's linearity and accuracy for the affected analyte.

Question 15

A medical laboratory has recently introduced a novel chemiluminescence immunoassay for a rare autoimmune marker. The laboratory\'s R&D department has successfully validated the assay\'s performance characteristics using a limited number of samples and has documented these findings. However, before commencing routine patient testing, the laboratory has not yet developed a formal, step-by-step standard operating procedure (SOP) for the assay\'s integration into the daily workflow, nor has it conducted specific verification studies to confirm the assay\'s performance on the exact analytical platform and with the specific reagent lots that will be used in routine operations. According to the principles outlined in ISO 15189:2022, what critical deficiency exists in the laboratory\'s approach to ensuring the suitability of this new examination process?

Accepted Answer

Absence of a documented procedure and system-specific verification for routine use of the new immunoassay.

Question 16

A medical laboratory accredited to ISO 15189:2022 receives a request for a comprehensive lipid panel and a thyroid-stimulating hormone (TSH) assay. Upon visual inspection of the collected blood sample, the phlebotomist notes that the serum volume is only 0.5 mL, whereas the standard operating procedure for the lipid panel requires a minimum of 1.0 mL of serum, and the TSH assay requires 0.5 mL of serum. Considering the laboratory\'s commitment to accurate and reliable results, what is the most appropriate action to take regarding this sample?

Accepted Answer

Reject the sample and inform the requesting clinician of the insufficient volume for the lipid panel, offering to proceed with the TSH assay if the clinician agrees.

Question 17

A medical laboratory, accredited to ISO 15189:2022, routinely performs a specific immunoassay for thyroid-stimulating hormone (TSH). Due to a supply chain disruption from their usual certified vendor, the laboratory manager authorizes the use of a reagent lot from a newly identified, unapproved supplier. This reagent was introduced into the workflow without undergoing the laboratory\'s documented verification process for new reagent lots or alternative suppliers. Subsequently, several patient results from this assay showed unexpected deviations from historical trends and clinical expectations. What fundamental aspect of ISO 15189:2022 quality management has been most critically overlooked in this scenario?

Accepted Answer

The laboratory's failure to perform documented verification of the suitability of the new reagent lot before its routine use.

Question 18

A medical laboratory accredited to ISO 15189:2022 is performing a high-sensitivity cardiac troponin assay. Following the introduction of a new lot of a critical calibrator, the laboratory observes a subtle but persistent shift in the mean results for a set of internal quality control materials. Despite the shift remaining within the laboratory\'s established acceptable limits for QC, the laboratory director is concerned about potential implications for patient results, particularly for individuals requiring precise interpretation of borderline values. Which of the following actions best reflects the laboratory\'s commitment to quality management and patient safety under ISO 15189:2022 in this scenario?

Accepted Answer

Immediately halt the use of the new calibrator lot, investigate the cause of the QC shift, re-evaluate all patient results generated with the suspect lot, and implement a robust verification process for the new lot before reintroducing it.

Question 19

A medical laboratory accredited to ISO 15189:2022 receives a request for a complex biochemical assay. Upon retrieval from storage, the phlebotomist\'s handwritten label on the primary collection tube appears smudged, rendering the patient\'s full name illegible, though the unique patient identification number is still discernible. The secondary specimen container, which was also labeled, has a label that is completely detached. Considering the stringent requirements for specimen traceability and integrity, what is the most appropriate immediate action for the laboratory to take to uphold the principles of ISO 15189:2022 and ensure patient safety?

Accepted Answer

Halt all further examination of the specimen, initiate an investigation to confirm the patient's identity and the specimen's suitability for testing, and communicate the discrepancy to the requesting healthcare professional.

Question 20

A medical laboratory is implementing a new immunoassay for a critical analyte. To ensure compliance with ISO 15189:2022, what is the most robust approach for establishing and maintaining traceability of the measurement results for this analyte?

Accepted Answer

Utilizing certified reference materials (CRMs) traceable to national or international metrological standards, and ensuring that the laboratory's calibration procedures are directly linked to these CRMs through validated methods.

Question 21

A clinical laboratory receives a blood sample for a complete blood count (CBC) from a large hospital. Upon initial review of the accompanying request form, the laboratory technician notices that the patient\'s date of birth has been inadvertently omitted. The laboratory has established procedures for sample acceptance and rejection based on ISO 15189:2022 requirements. Considering the potential implications for patient identification and result reporting, what is the most appropriate immediate action for the laboratory to take?

Accepted Answer

Reject the sample and request the missing date of birth from the requester before proceeding with the examination.

Question 22

A clinical laboratory, accredited to ISO 15189:2022, is processing a high volume of urgent patient samples. A critical reagent for a specific immunoassay, vital for timely diagnosis, arrives and is immediately put into use without undergoing the full lot verification protocol due to extreme time constraints. Subsequently, a quality control deviation is noted during routine monitoring, raising concerns about the integrity of the reagent. What is the most appropriate immediate course of action for the laboratory to mitigate potential risks to patient results and uphold the requirements of the standard?

Accepted Answer

Re-examine all patient samples tested with the unverified reagent lot to ensure the accuracy and reliability of the results.

Question 23

A clinical laboratory receives a serum sample for a complex biochemical assay requested by an oncologist for a patient undergoing chemotherapy. Upon visual inspection, the specimen exhibits significant hemolysis, indicated by a visibly pinkish-red discoloration. The laboratory\'s standard operating procedure for specimen handling, aligned with ISO 15189:2022 requirements for pre-examination processes, outlines specific criteria for specimen rejection. Considering the potential impact of hemolysis on the accuracy of biochemical measurements and the laboratory\'s commitment to providing reliable results, what is the most appropriate immediate action the laboratory should take?

Accepted Answer

Reject the specimen due to significant hemolysis and inform the requesting clinician, documenting the reason for rejection and the need for a new sample.

Question 24

A medical laboratory accredited to ISO 15189:2022 is implementing a new batch of a critical diagnostic reagent for a highly sensitive immunoassay. The supplier has provided a certificate of analysis (CoA) for the batch, detailing its specifications and manufacturing date. To fully comply with the standard\'s requirements regarding the quality of examination procedures, what is the most comprehensive approach the laboratory should adopt for this new reagent batch?

Accepted Answer

Conduct an internal verification of the reagent's performance characteristics using a panel of characterized samples, and maintain documented records of this verification, including storage conditions and lot-specific performance data.

Question 25

A medical laboratory receives a blood sample for a complex panel of tests, including genetic sequencing and specialized protein analysis. Upon initial visual inspection, the phlebotomist notes that the sample volume is significantly less than what is typically required for the full panel, particularly for the genetic sequencing component. The laboratory\'s standard operating procedure for sample receipt requires verification of sample adequacy for all requested examinations. What is the most appropriate action for the laboratory to take in this scenario, adhering to the principles outlined in ISO 15189:2022 regarding sample acceptance?

Accepted Answer

Reject the sample due to insufficient volume and inform the requesting healthcare professional of the reason for rejection.

Question 26

A medical laboratory consistently receives unsatisfactory performance reports from an external quality assessment (EQA) program for a specific quantitative immunoassay used for monitoring therapeutic drug levels. Despite recalibrating the instrument and ensuring adequate internal quality control measures are in place, the EQA samples continue to fall outside the acceptable performance limits. Which of the following actions best reflects the laboratory\'s responsibility under ISO 15189:2022 to address this persistent issue and ensure the integrity of patient results?

Accepted Answer

Initiate a comprehensive root cause analysis of the entire immunoassay testing process, including pre-examination variables, analytical system performance, reagent integrity, and post-examination procedures, to identify and rectify the underlying cause of the repeated EQA failures.

Question 27

A medical laboratory has been using a validated immunoassay for quantifying a specific biomarker. Due to supply chain issues, the laboratory must switch to a new reagent kit from a different manufacturer for the same assay. This new kit utilizes a slightly different buffer composition and a modified incubation step. What is the most appropriate action the laboratory must take to ensure the continued fitness for purpose of this examination procedure according to ISO 15189:2022?

Accepted Answer

Perform a full re-validation of the modified examination procedure to confirm its analytical performance characteristics.

Question 28

A medical laboratory accredited to ISO 15189:2022 is implementing a new lot of a critical calibrator for a high-sensitivity troponin immunoassay. The manufacturer has provided a certificate of analysis for the new lot, indicating it meets all stated specifications. However, the laboratory\'s internal quality policy, derived from ISO 15189:2022 requirements for managing examination materials, mandates an independent verification of any new lot of critical calibrators before their routine integration into patient sample analysis. What is the most appropriate course of action for the laboratory to ensure compliance and maintain the integrity of its testing process?

Accepted Answer

Conduct a comprehensive verification of the new calibrator lot, comparing its performance against established criteria and potentially the previous lot, before releasing it for routine use.

Question 29

A medical laboratory accredited to ISO 15189:2022 is reviewing its quality management system for the pre-analytical phase. The laboratory director is concerned about potential variability introduced by the diverse range of reagents and consumables used across its various analytical platforms. Which of the following activities most directly addresses the laboratory\'s fundamental obligation under the standard to ensure the quality and suitability of all inputs that could impact examination results?

Accepted Answer

Implementing a robust system for the receipt, identification, storage, and verification of suitability for all reagents, consumables, and materials used in examination processes.

Question 30

Consider a scenario at a busy clinical laboratory where a technician, under pressure to meet turnaround times, fails to meticulously verify the patient\'s full name and date of birth against the requisition form and the sample label for a critical diagnostic test. The sample appears visually intact, and the initial analytical steps proceed without any instrument flags. However, upon review of the completed report, a discrepancy is noted between the patient\'s demographic information on the requisition and the information recorded in the laboratory information system for the sample. What is the most appropriate immediate course of action for the laboratory director to ensure compliance with ISO 15189:2022 and protect patient safety?

Accepted Answer

Immediately halt the reporting of all results associated with the suspect sample and initiate a full investigation into the pre-examination process failure.

ISO 15189:2022 - Medical Laboratory Examination Processes Professional Free Practice Test — 30 Questions

A lot more is already mapped out

About the ISO 15189:2022 - Medical Laboratory Examination Processes Professional Certification